ProfileGDS5678 / 1438016_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 88% 90% 88% 90% 89% 88% 92% 90% 88% 91% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.829388
GSM967853U87-EV human glioblastoma xenograft - Control 26.9120588
GSM967854U87-EV human glioblastoma xenograft - Control 36.9292588
GSM967855U87-EV human glioblastoma xenograft - Control 47.3787290
GSM967856U87-EV human glioblastoma xenograft - Control 56.8925588
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9180290
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9046789
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8202488
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4849992
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1627390
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.896888
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5409491
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0523789
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0209989